Current and Potential Roles of Ferroptosis in Bladder Cancer

Abstract

Ferroptosis, a type of regulated cell death driven by iron-dependent lipid peroxidation, is mainly initiated by extramitochondrial lipid peroxidation due to the accumulation of iron-dependent reactive oxygen species. Ferroptosis is a prevalent and primitive form of cell death. Numerous cellular metabolic processes regulate ferroptosis, including redox homeostasis, iron regulation, mitochondrial activity, amino acid metabolism, lipid metabolism, and various disease-related signaling pathways. Ferroptosis plays a pivotal role in cancer therapy, particularly in the eradication of aggressive malignancies resistant to conventional treatments. Multiple studies have explored the connection between ferroptosis and bladder cancer, focusing on its incidence and treatment outcomes. Several biomolecules and tumor-associated signaling pathways, such as p53, heat shock protein 1, nuclear receptor coactivator 4, RAS-RAF-MEK, phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin, and the Hippo-tafazzin signaling system, exert a moderating influence on ferroptosis in bladder cancer. Ferroptosis inducers, including erastin, artemisinin, conjugated polymer nanoparticles, and quinazolinyl-arylurea derivatives, hold promise for enhancing the effectiveness of conventional anticancer medications in bladder cancer treatment. Combining conventional therapeutic drugs and treatment methods related to ferroptosis offers a promising approach for the treatment of bladder cancer. In this review, we analyze the research on ferroptosis to augment the efficacy of bladder cancer treatment.

Keywords

ferroptosis / bladder cancer / ferroptosis-associated tumor signaling pathway / ferroptosis inducer

References

[1]	Richters A, Aben K, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol, 2020,38(8):1895–1904
[2]	Xia QD, Sun JX, Liu CQ, et al. Ferroptosis Patterns and Tumor Microenvironment Infiltration Characterization in Bladder Cancer. Front Cell Dev Biol, 2022,10:832892
[3]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023,73(1):17–48
[4]	Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol, 2021,79(4):480–488
[5]	Lenis AT, Lec PM, Chamie K, et al. Bladder Cancer: A Review. JAMA, 2020,324(19):1980–1991
[6]	Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol, 2021,79(1):82–104
[7]	Hanna N, Trinh QD, Seisen T, et al. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol, 2018,1(1):83–90
[8]	Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer, 2021,20(1):28
[9]	Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science, 2020,368(6487):eaaw5473
[10]	Shen L, Zhang J, Zheng Z, et al. PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. Int J Biol Sci, 2022,18(14):5459–5474
[11]	Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol, 2019,12(1):34
[12]	Zaffaroni N, Beretta GL. Ferroptosis Inducers for Prostate Cancer Therapy. Curr Med Chem, 2022,29(24):4185–4201
[13]	Tang D, Chen X, Kang R, et al. Ferroptosis: molecular mechanisms and health implications. Cell Res, 2021,31(2):107–125
[14]	Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell, 2003,3(3):285–296
[15]	Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature, 2007,447(7146):864–868
[16]	Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol, 2008,15(3):234–245
[17]	Zhao S, Li P, Wu W, et al. Roles of ferroptosis in urologic malignancies. Cancer Cell Int, 2021,21(1):676
[18]	Doll S, Conrad M. Iron and ferroptosis: A still ill-defined liaison. IUBMB Life, 2017,69(6):423–434
[19]	Chen Y, Fan Z, Hu S, et al. Ferroptosis: A New Strategy for Cancer Therapy. Front Oncol, 2022,12:830561
[20]	Bai T, Lei P, Zhou H, et al. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells. J Cell Mol Med, 2019,23(11):7349–7359
[21]	Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA, 2014,111(47):16836–16841
[22]	Gammella E, Recalcati S, Rybinska I, et al. Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms. Oxid Med Cell Longev, 2015,2015:230182
[23]	Liang C, Zhang X, Yang M, et al. Recent Progress in Ferroptosis Inducers for Cancer Therapy. Adv Mater, 2019,31(51):e1904197
[24]	Kindrat I, Tryndyak V, de Conti A, et al. MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis. Oncotarget, 2016,7(2):1276–1287
[25]	Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell, 2017,171(2):273–285
[26]	Yan HF, Zou T, Tuo QZ, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther, 2021,6(1):49
[27]	Sun X, Ou Z, Xie M, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene, 2015,34(45):5617–5625
[28]	Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell, 2019,35(6):830–849
[29]	Wang H, Lin D, Yu Q, et al. A Promising Future of Ferroptosis in Tumor Therapy. Front Cell Dev Biol, 2021,9:629150
[30]	Zhang JJ, Du J, Kong N, et al. Mechanisms and pharmacological applications of ferroptosis: a narrative review. Ann Transl Med, 2021,9(19):1503
[31]	D’Herde K, Krysko DV. Ferroptosis: Oxidized PEs trigger death. Nat Chem Biol, 2017,13(1):4–5
[32]	Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun, 2017,482(3):419–425
[33]	Feng H, Stockwell BR. Unsolved mysteries: How does lipid peroxidation cause ferroptosis. PLoS Biol, 2018,16(5):e2006203
[34]	Takashi Y, Tomita K, Kuwahara Y, et al. Mitochondrial dysfunction promotes aquaporin expression that controls hydrogen peroxide permeability and ferroptosis. Free Radic Biol Med, 2020,161:60–70
[35]	Kuhn H, Humeniuk L, Kozlov N, et al. The evolutionary hypothesis of reaction specificity of mammalian ALOX15 orthologs. Prog Lipid Res, 2018,72:55–74
[36]	Dar HH, Tyurina YY, Mikulska-Ruminska K, et al. Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. J Clin Invest, 2018,128(10):4639–4653
[37]	Zeng F, Lan Y, Wang N, et al. Ferroptosis: A new therapeutic target for bladder cancer. Front Pharmacol, 2022,13:1043283
[38]	Yang WS, Kim KJ, Gaschler MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci USA, 2016,113(34):E4966–E4975
[39]	Ou Y, Wang SJ, Li D, et al. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci USA, 2016,113(44):E6806–E6812
[40]	Chen X, Kang R, Kroemer G, et al. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol, 2021,18(5):280–296
[41]	Angeli J, Shah R, Pratt DA, et al. Ferroptosis Inhibition: Mechanisms and Opportunities. Trends Pharmacol Sci, 2017,38(5):489–498
[42]	Jennis M, Kung CP, Basu S, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev, 2016,30(8):918–930
[43]	Wang Y, Ma Y, Jiang K. The role of ferroptosis in prostate cancer: a novel therapeutic strategy. Prostate Cancer Prostatic Dis, 2023,26(1):25–29
[44]	Song X, Zhu S, Chen P, et al. AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc- Activity. Curr Biol, 2018,28(15):2388–2399
[45]	Cao JY, Poddar A, Magtanong L, et al. A Genome-wide Haploid Genetic Screen Identifies Regulators of Glutathione Abundance and Ferroptosis Sensitivity. Cell Rep, 2019,26(6):1544–1556.e8
[46]	Xie Y, Zhu S, Song X, et al. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Rep, 2017,20(7):1692–1704
[47]	Zhang Y, Shi J, Liu X, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol, 2018,20(10):1181–1192
[48]	Martin-Sanchez D, Fontecha-Barriuso M, Sanchez-Nino MD, et al. Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields. Cell Death Dis, 2018,9(2):118
[49]	Mazdak H, Yazdekhasti F, Movahedian A, et al. The comparative study of serum iron, copper, and zinc levels between bladder cancer patients and a control group. Int Urol Nephrol, 2010,42(1):89–93
[50]	Guo P, Wang L, Shang W, et al. Intravesical In Situ Immunostimulatory Gel for Triple Therapy of Bladder Cancer. ACS Appl Mater Interfaces, 2020,12(49):54367–54377
[51]	Qi A, Wang C, Ni S, et al. Intravesical Mucoadhesive Hydrogel Induces Chemoresistant Bladder Cancer Ferroptosis through Delivering Iron Oxide Nanoparticles in a Three-Tier Strategy. ACS Appl Mater Interfaces, 2021,13(44):52374–52384
[52]	Jasim KA, Gesquiere AJ. Ultrastable and Bio-functionalizable Conjugated Polymer Nanoparticles with Encapsulated Iron for Ferroptosis Assisted Chemodynamic Therapy. Mol Pharm, 2019,16(12):4852–4866
[53]	Kong N, Chen X, Feng J, et al. Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1. Acta Pharm Sin B, 2021,11(12):4045–4054
[54]	Hao X, Fan H, Yang J, et al. Network Pharmacology Research and Dual-omic Analyses Reveal the Molecular Mechanism of Natural Product Nodosin Inhibiting Muscle-Invasive Bladder Cancer in Vitro and in Vivo. J Nat Prod, 2022,85(8):2006–2017
[55]	Goldstein JT, Berger AC, Shih J, et al. Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer. Cancer Res, 2017,77(24):6987–6998
[56]	Cao R, Wang G, Qian K, et al. TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARγ-SIRTl feedback loop in human bladder cancer cells. Cancer Lett, 2018,414:278–293
[57]	Rochel N, Krucker C, Coutos-Thévenot L, et al. Recurrent activating mutations of PPARγ associated with luminal bladder tumors. Nat Commun, 2019,10(1):253
[58]	Galbraith L, Mui E, Nixon C, et al. PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer. Oncogene, 2021,40(13):2355–2366
[59]	Liu S, Shi J, Wang L, et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free Radic Biol Med, 2022,189:42–57
[60]	Hao J, Zhang W, Huang Z. Bupivacaine modulates the apoptosis and ferroptosis in bladder cancer via phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Bioengineered, 2022,13(3):6794–6806
[61]	Xiang Y, Chen X, Wang W, et al. Natural Product Erianin Inhibits Bladder Cancer Cell Growth by Inducing Ferroptosis via NRF2 Inactivation. Front Pharmacol, 2021,12:775506
[62]	Luo W, Wang J, Xu W, et al. LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. Cell Death Dis, 2021,12(11):1043
[63]	Liu T, Jiang L, Tavana O, et al. The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11. Cancer Res, 2019,79(8):1913–1924
[64]	Shimada K, Skouta R, Kaplan A, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol, 2016,12(7):497–503
[65]	Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer, 2013,13(8):572–583
[66]	Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell, 2017,168(6):960–976
[67]	Liu ST, Hui G, Mathis C, et al. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Clin Genitourin Cancer, 2018,16(2):e269–e276
[68]	Sun Y, Berleth N, Wu W, et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. Cell Death Dis, 2021,12(11):1028
[69]	Chen JN, Li T, Cheng L, et al. Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives. Eur J Med Chem, 2020,205:112661
[70]	Nie Z, Chen M, Gao Y, et al. Regulated Cell Death in Urinary Malignancies. Front Cell Dev Biol, 2021,9:789004
[71]	Zhao Y, Ren P, Yang Z, et al. Inhibition of SND1 overcomes chemoresistance in bladder cancer cells by promoting ferroptosis. Oncol Rep, 2023,49(1):16
[72]	Chen JJ, Galluzzi L. Fighting Resilient Cancers with Iron. Trends Cell Biol, 2018,28(2):77–78
[73]	Zhao F, Vakhrusheva O, Markowitsch SD, et al. Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction. Cells, 2020,9(12):2643
[74]	Guo J, Xu B, Han Q, et al. Ferroptosis: A Novel Anti-tumor Action for Cisplatin. Cancer Res Treat, 2018,50(2):445–460
[75]	Wang Y, Zhang S, Bai Y, et al. Development and Validation of Ferroptosis-Related LncRNA Biomarker in Bladder Carcinoma. Front Cell Dev Biol, 2022,10:809747
[76]	Xiao K, Zhang N, Li F, et al. Pro-oxidant response and accelerated ferroptosis caused by synergetic Au(I) release in hypercarbon-centered gold(I) cluster prodrugs. Nat Commun, 2022,13(1):4669\r\nYu H, Guo P, Xie X, et al. Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med, 2017,21(4):648–657
[77]	Flaig TW, Spiess PE, Agarwal N, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2020,18(3):329–354
[78]	Doroud D, Hozouri H. Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma. Iran Biomed J, 2022,26(5):340–349
[79]	Ma C, Wu X, Zhang X, et al. Heme oxygenase-1 modulates ferroptosis by fine-tuning levels of intracellular iron and reactive oxygen species of macrophages in response to Bacillus Calmette-Guerin infection. Front Cell Infect Microbiol, 2022,12:1004148
[80]	Du Y, Miao W, Jiang X, et al. The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis. Front Oncol, 2021,11:683951
[81]	Cheng X, Wang Y, Li Y, et al. Quantification of ferroptosis pattern in bladder carcinoma and its significance on immunotherapy. Sci Rep, 2022,12(1):9066\r\nCao R, Yuan L, Ma B, et al. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunol Immunother, 2021,70(1):1–18
[82]	Wan C, Sun Y, Tian Y, et al. Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv, 2020,6(13):eaay9789
[83]	Lang X, Green MD, Wang W, et al. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer Discov, 2019,9(12):1673–1685
[84]	Lei G, Zhang Y, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res, 2020,30(2):146–162
[85]	Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 2019,569(7755):270–274
[86]	Garg AD, Agostinis P. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunol Rev, 2017,280(1):126–148
[87]	Kim SE, Zhang L, Ma K, et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat Nanotechnol, 2016,11(11):977–985
[88]	Taber A, Christensen E, Lamy P, et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun, 2020,11(1):4858
[89]	Mirzaei S, Paskeh M, Hashemi F, et al. Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies. Life Sci, 2022,288:119948
[90]	Wang M, Mao C, Ouyang L, et al. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ, 2019,26(11):2329–2343
[91]	Luo WJ, Tian X, Xu WH, et al. Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. J Cell Mol Med, 2021,25(9):4326–4339
[92]	Wang L, Wu S, He H, et al. CircRNA-ST6GALNAC6 increases the sensitivity of bladder cancer cells to erastin-induced ferroptosis by regulating the HSPB1/P38 axis. Lab Invest, 2022,102(12):1323–1334
[93]	Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc, 2014,136(12):4551–4556
[94]	Yan Y, Cai J, Huang Z, et al. A Novel Ferroptosis-Related Prognostic Signature Reveals Macrophage Infiltration and EMT Status in Bladder Cancer. Front Cell Dev Biol, 2021,9:712230
[95]	Yi K, Liu J, Rong Y, et al. Biological Functions and Prognostic Value of Ferroptosis-Related Genes in Bladder Cancer. Front Mol Biosci, 2021,8:631152
[96]	Jiang P, Ning J, Yu W, et al. FLRT2 suppresses bladder cancer progression through inducing ferroptosis. J Cell Mol Med, 2023. doi:https://doi.org/10.1111/jcmm.17855
[97]	Hu CY, Wu HT, Shan YS, et al. Evodiamine Exhibits Anti-Bladder Cancer Activity by Suppression of Glutathione Peroxidase 4 and Induction of Ferroptosis. Int J Mol Sci, 2023,24(7):6021
[98]	Xu Y, Tong Y, Lei Z, et al. Abietic acid induces ferroptosis via the activation of the HO-1 pathway in bladder cancer cells. Biomed Pharmacother, 2023,158:114154